Related Experiment Video
Updated: Feb 19, 2026
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
The Effect of the Targeted Recombinant Toxin DARPin-PE40 on the Dynamics of HER2-Positive Tumor Growth
E A Sokolova1,2, G M Proshkina1, O M Kutova2
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Str., 16/10, Moscow, 117997, Russia.
Abstract:
The development of targeted toxins based on non-immunoglobulin targeting molecules appears to be one of the most advanced approaches in the targeted therapy of malignant tumors with a high expression of the HER2 receptor. Earlier, we showed that the targeted toxin DARPin-PE40 consisting of the HER2-specific non-immunoglobulin polypeptide (the targeting module) and a fragment of Pseudomonas exotoxin A (the toxic module) exhibits an antitumor effect in vivo against the HER2-positive adenocarcinoma xenograft. In this work, an in-depth analysis of the effect of DARPin-PE40 on the growth dynamics of experimental xenograft tumors was carried out. DARPin-PE40 was shown to inhibit tumor growth at a dose of 25 and 50 μg/animal and to cause tumor node reduction at a dose of 80 μg/animal, followed by growth resumption at the end of therapy. An evaluation of the tumor growth dynamics revealed statistically significant differences in tumor volume in mice in the experimental groups compared to the control group. The results testify to the potential of using the created targeted toxin as an agent for the targeted therapy of HER2-overexpressing tumors.
Insights
The targeted toxin DARPin-PE40 effectively inhibits HER2-positive tumor growth in preclinical models. This study analyzes its dose-dependent effects, showing potential for HER2-overexpressing cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapy is advancing for HER2-receptor-positive malignant tumors.
- Non-immunoglobulin targeting molecules are key in developing novel cancer toxins.
- Previous work demonstrated DARPin-PE40's antitumor effect in HER2-positive xenografts.
Purpose of the Study:
- To conduct an in-depth analysis of DARPin-PE40's impact on experimental xenograft tumor growth dynamics.
- To evaluate the dose-dependent efficacy of DARPin-PE40 in a preclinical setting.
Main Methods:
- Utilized a xenograft tumor model in mice.
- Administered varying doses of DARPin-PE40 (25, 50, and 80 μg/animal).
- Monitored and analyzed tumor growth dynamics and volume over time.
Main Results:
- DARPin-PE40 demonstrated dose-dependent inhibition of tumor growth at 25 and 50 μg/animal.
- A dose of 80 μg/animal led to tumor node reduction, with subsequent growth resumption.
- Statistically significant differences in tumor volume were observed compared to the control group.
Conclusions:
- DARPin-PE40 shows potential as a therapeutic agent for HER2-overexpressing tumors.
- The study highlights the efficacy of targeted toxins utilizing non-immunoglobulin scaffolds.
- Further investigation into DARPin-PE40's therapeutic application in HER2-positive cancers is warranted.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
